Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer

World Journal of Clinical Oncology

Volumn 5, Issue 5, 2014, Pages 1048-1054

  Yano, Tokujiro ^a   Okamoto, Tatsuro ^b   Fukuyama, Seiichi ^a   Maehara, Yoshihiko ^b  

^a NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Distant metastasis; Local treatment; Locoregional recurrence; Non small cell lung cancer; Oligometastases; Postoperative recurrence

Indexed keywords

EID: 84928646475     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i5.1048     Document Type: Review

References (42)

1. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714 [PMID: 17762336 DOI: 10.1097/JTO.0b013e31812f3c1a]
2. Yano T, Hara N, Ichinose Y, Asoh H, Yokoyama H, Ohta M, Hata K. Local recurrence after complete resection for non-small-cell carcinoma of the lung. Significance of local control by radiation treatment. J Thorac Cardiovasc Surg 1994; 107: 8-12 [PMID: 8283923]
3. Ichinose Y, Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Takanashi N. Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg 1994; 108: 158-161 [PMID: 8028360]
4. Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C, Williams BA, Pairolero PC. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007; 83: 409-417; discussioin 417-418 [PMID: 17257962 DOI: 10.1016/j.athoracsur.2006.08. 046]
5. Saisho S, Yasuda K, Maeda A, Yukawa T, Okita R, Hirami Y, Shimizu K, Nakata M. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interact Cardiovasc Thorac Surg 2013; 16: 166-172 [PMID: 23143203 DOI: 10.1093/icvts/ivs450]
6. Yano T, Haro A, Yoshida T, Morodomi Y, Ito K, Shikada Y, Shoji F, Maruyama R, Maehara Y. Prognostic impact of local treatment against postoperative oligometastases in nonsmall cell lung cancer. J Surg Oncol 2010; 102: 852-855 [PMID: 20886558 DOI: 10.1002/jso.21750]
7. Nakagawa T, Okumura N, Ohata K, Igai H, Matsuoka T, Kameyama K. Postrecurrence survival in patients with stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2008; 34: 499-504 [PMID: 18579404 DOI: 10.1016/j.ejcts.2008.05.016]
8. Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Takai E, Ichinose Y. The first site of recurrence after complete resection in non-small-cell carcinoma of the lung. Comparison between pN0 disease and pN2 disease. J Thorac Cardiovasc Surg 1994; 108: 680-683 [PMID: 7934102]
9. Williams BA, Sugimura H, Endo C, Nichols FC, Cassivi SD, Allen MS, Pairolero PC, Deschamps C, Yang P. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg 2006; 81: 1021-1027 [PMID: 16488713 DOI: 10.1016/j.athoracsur.20 05.09.020]
10. Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes. J Thorac Cardiovasc Surg 1994; 107: 1398-1402 [PMID: 8196379]
11. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899-909 [PMID: 7580546 DOI: 10.1136/bmj.311.7010.899]
12. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98 [PMID: 11784875 DOI: 10.1056/NEJMoa011954]
13. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18: 317-323 [PMID: 17079694 DOI: 10.1093/annonc/mdl377]
14. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-4291 [PMID: 12409326 DOI: 10.1200/JCO.2002.02.068]
15. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247-255 [PMID: 22341744 DOI: 10.1016/S1470-2045(12)70063-3]
16. Botrel TE, Clark O, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. Lung Cancer 2011; 74: 89-97 [PMID: 21377753 DOI: 10.1016/j.lungcan.2011.01.028]
17. Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2011; 6: e22681 [PMID: 21829644 DOI: 10.1371/journal. pone.0022681]
18. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013; 31: 3004-3011 [PMID: 23835708 DOI: 10.1200/JCO.2012.42.3749]
19. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and beva-cizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31: 4349-4357 [PMID: 24145346 DOI: 10.1200/JCO.2012.47.9626]
20. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139 [PMID: 15118073 DOI: 10.1056/NEJMoa040938]
21. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967 [PMID: 19692684 DOI: 10.1056/NEJMoa0904554]
22. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-8923 [PMID: 15604253 DOI: 10.1158/0008-5472.CAN-04-2818]
23. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128 [PMID: 20022809 DOI: 10.1016/S1470-2045(09)70364-X]
24. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388 [PMID: 20573926 DOI: 10.1056/NEJMoa0909530]
25. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742 [PMID: 21783417 DOI: 10.1016/S1470-2045(11)70184-X]
26. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246 [PMID: 22285168 DOI: 10.1016/S1470-2045(11)70393-X]
27. Goto K, Nishio M, Yamamoto N, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Fukuyama T, Tamura T. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutationpositive advanced non-small-cell lung cancer (NSCLC). Lung Cancer 2013; 82: 109-114 [PMID: 23910906 DOI: 10.1016/j.lungcan.2013.07.003]
28. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566 [PMID: 17625570 DOI: 10.1038/nature05945]
29. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-4283 [PMID: 18594010 DOI: 10.1158/1078-0432.CCR-08-0168]
30. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-smallcell lung cancer. N Engl J Med 2010; 363: 1693-1703 [PMID: 20979469 DOI: 10.1056/NEJMoa1006448]
31. Macdermed DM, Weichselbaum RR, Salama JK. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 2008; 98: 202-206 [PMID: 18618604 DOI: 10.1002/jso.21102]
32. Hishida T, Nagai K, Yoshida J, Nishimura M, Ishii G, Iwasaki M, Nishiwaki Y. Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? J Thorac Cardiovasc Surg 2006; 131: 838-842 [PMID: 16580442 DOI: 10.1016/j.jtcvs.2005.11.028]
33. Mariya Y, Sekizawa G, Matsuoka Y, Seki H, Sugawara T. Outcome of stereotactic radiosurgery for patients with nonsmall cell lung cancer metastatic to the brain. J Radiat Res 2010; 51: 333-342 [PMID: 20383028 DOI: 10.1269/jrr.90130]
34. Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, Bepler G. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008; 26: 1142-1147 [PMID: 18309950 DOI: 10.1200/JCO.2007.14.2091]
35. Yano T, Okamoto T, Haro A, Fukuyama S, Yoshida T, Kohno M, Maehara Y. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung Cancer 2013; 82: 431-435 [PMID: 24113550 DOI: 10.1016/j.lungcan.2013.08.006]
36. Toba H, Sakiyama S, Otsuka H, Kawakami Y, Takizawa H, Kenzaki K, Kondo K, Tangoku A. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic nonsmall-cell lung cancer patients. Interact Cardiovasc Thorac Surg 2012; 15: 859-864 [PMID: 22914804 DOI: 10.1093/icvts/ivs368]
37. Okami J, Nishiyama K, Fujiwara A, Konishi K, Kanou T, Tokunaga T, Teshima T, Higashiyama M. Radiotherapy for postoperative thoracic lymph node recurrence of non-smallcell lung cancer provides better outcomes if the disease is asymptomatic and a single-station involvement. J Thorac Oncol 2013; 8: 1417-1424 [PMID: 24077458 DOI: 10.1097/JTO.0b013e3182a5097b]
38. Kagami Y, Nishio M, Narimatsu N, Mjoujin M, Sakurai T, Hareyama M, Saito A. Radiotherapy for locoregional recurrent tumors after resection of non-small cell lung cancer. Lung Cancer 1998; 20: 31-35 [PMID: 9699185 DOI: 10.1016/S0169-5002(98)00008-7]
39. Jeremic B, Shibamoto Y, Milicic B, Milisavljevic S, Nikolic N, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G. External beam radiation therapy alone for loco-regional recurrence of non-small-cell lung cancer after complete resection. Lung Cancer 1999; 23: 135-142 [PMID: 10217617 DOI: 10.1016/S0169-5002(99)00007-0]
40. Tada T, Fukuda H, Nakagawa K, Matsui K, Hosono M, Takada Y, Inoue Y. Non-small cell lung cancer: radiation therapy for locoregional recurrence after complete resection. Int J Clin Oncol 2005; 10: 425-428 [PMID: 16369747 DOI: 10.1007/s10147-005-0526-5]
41. Okawara G, Mackay JA, Evans WK, Ung YC. Management of unresected stage III non-small cell lung cancer: a systematic review. J Thorac Oncol 2006; 1: 377-393 [PMID: 17409887 DOI: 10.1097/01243894-200605000-00019]
42. Yano T, Maehara Y. Lung carcinoma surveillance counterpoint: Japan. In: Patient Surveillance After Cancer Treatment. New York: Human Press, 2013: 79-81